Literature DB >> 15005849

Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.

Kenneth M Kozloff1, Angela Carden, Clemens Bergwitz, Antonella Forlino, Thomas E Uveges, Michael D Morris, Joan C Marini, Steven A Goldstein.   

Abstract

UNLABELLED: The Brtl mouse model for type IV osteogenesis imperfecta improves its whole bone strength and stiffness between 2 and 6 months of age. This adaptation is accomplished without a corresponding improvement in geometric resistance to bending, suggesting an improvement in matrix material properties.
INTRODUCTION: The Brittle IV (Brtl) mouse was developed as a knock-in model for osteogenesis imperfecta (OI) type IV. A Gly349Cys substitution was introduced into one col1a1 allele, resulting in a phenotype representative of the disease. In this study, we investigate the effect of the Brtl mutation on whole bone architecture, strength, and composition across a range of age groups.
MATERIALS AND METHODS: One-, 2-, 6-, and 12-month-old Brtl and wildtype (WT) mice were analyzed. Femurs were assessed at the central diaphysis for cortical geometric parameters using microCT and were subsequently mechanically tested to failure by four-point bending. Matrix material properties were predicted using microCT data to normalize data from mechanical tests. Raman spectroscopy and DXA were used to assess matrix composition.
RESULTS: Our findings show a postpubertal adaptation in which Brtl femoral strength and stiffness increase through a mechanism independent of changes in whole bone geometry. These findings suggest an improvement in the material properties of the bone matrix itself, rather than improvements in whole bone geometry, as seen in previous mouse models of OI. Raman spectroscopic results suggest these findings may be caused by changes in mineral/matrix balance rather than improvements in mineral crystallinity.
CONCLUSIONS: Our findings parallel the currently unexplained clinical observation of decreased fractures in human OI patients after puberty. The Brtl mouse remains an important tool for investigating therapeutic interventions for OI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15005849     DOI: 10.1359/JBMR.040111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  54 in total

Review 1.  Functional interactions among morphologic and tissue quality traits define bone quality.

Authors:  Karl J Jepsen
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

2.  Infrared spectroscopic characterization of mineralized tissues.

Authors:  Adele L Boskey; Richard Mendelsohn
Journal:  Vib Spectrosc       Date:  2005-07-29       Impact factor: 2.507

3.  Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim).

Authors:  Stephanie M Carleton; Daniel J McBride; William L Carson; Carolyn E Huntington; Kristin L Twenter; Kristin M Rolwes; Christopher T Winkelmann; J Steve Morris; Jeremy F Taylor; Charlotte L Phillips
Journal:  Bone       Date:  2008-01-05       Impact factor: 4.398

4.  Finite element analysis of bone strength in osteogenesis imperfecta.

Authors:  Peter Varga; Bettina M Willie; Chris Stephan; Kenneth M Kozloff; Philippe K Zysset
Journal:  Bone       Date:  2020-01-22       Impact factor: 4.398

5.  Applying Full Spectrum Analysis to a Raman Spectroscopic Assessment of Fracture Toughness of Human Cortical Bone.

Authors:  Alexander J Makowski; Mathilde Granke; Oscar D Ayala; Sasidhar Uppuganti; Anita Mahadevan-Jansen; Jeffry S Nyman
Journal:  Appl Spectrosc       Date:  2017-07-14       Impact factor: 2.388

Review 6.  Contributions of Raman spectroscopy to the understanding of bone strength.

Authors:  Gurjit S Mandair; Michael D Morris
Journal:  Bonekey Rep       Date:  2015-01-07

7.  Single molecule effects of osteogenesis imperfecta mutations in tropocollagen protein domains.

Authors:  Alfonso Gautieri; Simone Vesentini; Alberto Redaelli; Markus J Buehler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.

Authors:  B P Sinder; L E White; J D Salemi; M S Ominsky; M S Caird; J C Marini; K M Kozloff
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

9.  RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.

Authors:  Renee Bargman; Alice Huang; Adele L Boskey; Cathleen Raggio; Nancy Pleshko
Journal:  Connect Tissue Res       Date:  2010-04       Impact factor: 3.417

10.  Transcutaneous Raman spectroscopy of murine bone in vivo.

Authors:  Matthew V Schulmerich; Jacqueline H Cole; Jaclynn M Kreider; Francis Esmonde-White; Kathryn A Dooley; Steven A Goldstein; Michael D Morris
Journal:  Appl Spectrosc       Date:  2009-03       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.